Saudi Arabia at a glance
- Population
- 37.0 million 2025
- Life expectancy at birth
- 79.0 years, 2024
- People aged 65 and over
- 3.1 % of people, 2025
- Health spending per person
- 1,825 US$ per person, 2023
- Doctors
- 3.41 per 1,000 people, 2023
Updated
Reviewed by Vidhi Upadhyay
Saudi Arabia Radiopharmaceuticals Market Industry Trends and Forecast to 2034: Segmented by (Type, Isotope, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$215.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $121.3 Mn | — | — |
| 2025 (base) | $134.9 Mn | +$13.6 Mn | — |
| 2026 (forecast) | $150.0 Mn | +$15.1 Mn | +11.2% |
| 2027 (forecast) | $166.8 Mn | +$16.8 Mn | +23.7% |
| 2028 (forecast) | $185.5 Mn | +$18.7 Mn | +37.5% |
| 2029 (forecast) | $206.3 Mn | +$20.8 Mn | +52.9% |
| 2030 (forecast) | $229.4 Mn | +$23.1 Mn | +70% |
| 2031 (forecast) | $255.1 Mn | +$25.7 Mn | +89.1% |
| 2032 (forecast) | $283.6 Mn | +$28.6 Mn | +110.2% |
| 2033 (forecast) | $315.4 Mn | +$31.8 Mn | +133.8% |
| 2034 (forecast) | $350.7 Mn | +$35.3 Mn | +160% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $134.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $350.7 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, isotope and end user (see all) |
| Key players | Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals and 1 more (see all) |
| Regulator in Saudi Arabia | SFDASource: Saudi Food and Drug Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Radiopharmaceuticals are drugs that carry a radioactive element to image or kill cancer cells.
Key segments of the radiopharmaceuticals market include type (Diagnostic and Therapeutic) and isotope (Lutetium-177, Actinium-225 and Fluorine-18).
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the radiopharmaceuticals market. Faster approvals and new combinations are improving survival.
Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the radiopharmaceuticals market.
High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the radiopharmaceuticals market, especially in low- and middle-income countries.
The radiopharmaceuticals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The Saudi Food and Drug Authority (SFDA) registers medicines before sale.[1] Citizens get free public care through the Ministry of Health, while most expatriate workers must have private health insurance, regulated by the Council of Health Insurance (CHI).[2]
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Council of Health Insurance. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for radiopharmaceuticals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.
What doctors and scientists are doing in Radiopharmaceuticals right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.
From our blog
Saudi Arabia · 1 shared keyword
Saudi Arabia
Saudi Arabia
Saudi Arabia
Saudi Arabia
Saudi Arabia
Digital Health · Saudi Arabia
Healthcare Services · Saudi Arabia
Healthcare Services · Saudi Arabia
Healthcare Services · Saudi Arabia
Public Health · Saudi Arabia
Medical Devices · Saudi Arabia